Selah Technologies Receives SBIR Grant to Accelerate Commercialization of Selah Dots

Selah Technologies, an advanced materials manufacturer, announced today that the company has received a $100,000 SBIR Phase I grant from the National Science Foundation (NSF) to fund continued manufacturing and development activities for the company's Selah Dots™ nanotechnology. This award is the second NSF SBIR Phase I grant received by the company.

Selah was recently notified of the award as part of the NSF’s Small Business Innovation Research (SBIR) program. “The awarding of this grant is continued validation of our efforts to develop and deploy Selah Dots™ across a variety of bioimaging and bio-sensing applications,” said Dr. Andrew Metters, Chief Technology Officer for Selah, who will lead the project.

Selah Technologies obtained a worldwide exclusive license in 2006 from Clemson University to develop and commercialize two nanotechnologies, branded Selah Dots™ and Selah Tubes™. Selah Dots™ are patent-pending brightly luminescent carbon based nanoparticles for use primarily as imaging agents for the biomedical industry with supplementary applications including solar cells and anticounterfeiting, among others. Selah Tubes™, enriched carbon nanotubes protected under US Patent No. 7,374,685, have a number of applications due to their impressive electrical and thermal conductivity properties.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.